Brief: Novakand Pharma Enters LOI With Svf Vaccines
22/12/2025 07:08
Dec 22 (Reuters) - Novakand Pharma AB NOVKAN.ST: NOVAKAND PHARMA ENTERS LETTER OF INTENT WITH SVF VACCINES REGARDING A REVERSE TAKEOVER EXISTING SHAREHOLDERS OF NOVAKAND WILL HOLD 33%, SVF SHAREHOLDERS 67% OF SHARES IN CO RATIO REFLECTS PARTIES' MUTUAL VALUATION OF NOVAKAND TO 27 MILLION SEK AND SVF TO 55 MILLION SEK Source text: ID:nMFN4hmjMB Further company coverage: NOVKAN.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Novakand Pharma AB
See all newsBrief: Nasdaq Decides To Delist Novakand From First North Growth Market
Brief: Novakand Pharma Extends Peter Selin's CEO Employment
Brief: Novakand Board Proposes New Business Direction, Relisting
Brief: Novakand Pharma Evaluates Options After Decision Not To Execute Reverse Take Over
Brief: Nasdaq Rejects Novakand's Application For Continued Listing